Don’t use DOACS in APS, regulator advises

Direct acting oral anticoagulants (DOACs) should not be used in patients with antiphospholipid syndrome (APS)  – including patients with SLE – due to a high risk of thrombotic events, the Therapeutic Goods Administration (TGA) has advised. In a new safety advisory statement the regulator says apixaban (Eliquis), dabigatran etexilate (Pradaxa) and rivaroxaban (Xarelto) are not ...

Already a member?

Login to keep reading.

© 2021 the limbic